|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's Range||0.6042 - 0.6370|
|52 Week Range||0.4440 - 1.2600|
|Beta (3Y Monthly)||7.73|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
Cannabis cultivation requires enormous amounts of energy, and water, and the companies that employ smart solutions are now pulling ahead in the highly competitive cannabis boom
HENDERSON, NV / ACCESSWIRE / April 9, 2019 / With some analysts calling for a potential recession, they are predicting the cannabis industry will be one of the top industries capable of delivering a healthy ...
Auxly Cannabis Group Inc. (TSX.V - XLY) ("Auxly" or the "Company") today announced that its wholly-owned subsidiary, Robinsons Cannabis Inc. (“Robinsons”), has been granted standard cultivation and processing licences by Health Canada pursuant to the Cannabis Act and Cannabis Regulations. The licences give Robinsons the ability to begin cultivation at its fully constructed 27,700 square-foot facility in Kentville, Nova Scotia, which was purpose-built to produce high-quality cannabis. Led by experienced head grower Andrew Robinson, Robinsons is uniquely positioned to capture the attention of luxury cannabis consumers, with operations built on a devotion to uncompromising quality and a premium cannabis experience.
With its ducks now in a row, Auxly readies itself to sell raw cannabis and derivative products in 2019.
Auxly Cannabis Group Inc. (XLY.V) (CBWTF) ("Auxly" or the "Company") today released its fourth quarter and full year 2018 financial results. The Company’s state-of-the-art processing facility at its wholly owned subsidiary Dosecann Inc. (“Dosecann”) and its highly-skilled team give the Company the ability to turn raw cannabis into derivative cannabis products.
In addition to lessened volatility, ancillary cannabis companies are not bogged down by bureaucratic limitations and have more freedom to make strategic acquisitions to bolster their portfolios. All in all, investors looking for potential opportunities could benefit from focusing on the cannabis industry in the coming months. Leafbuyer Technologies Inc (OTC:LBUY), Aphria Inc (NYSE: APHA, TSX: APHA), Auxly Cannabis Group Inc (CBWTF), and The Supreme Cannabis Company Inc (SPRWF) represent 4 marijuana stocks worth keeping on your radar on Tuesday.
HENDERSON, NV / ACCESSWIRE / March 20, 2019 / With cannabis in the news and investors becoming more and more hungry for the next big winner in the industry, we decided to highlight a couple that could ...
VANCOUVER, British Columbia, March 18, 2019 -- Auxly Cannabis Group Inc. (TSX.V - XLY) ("Auxly" or the "Company") today announced that it plans to report its fourth quarter and.
CORAL GABLES, FL / ACCESSWIRE / March 18, 2019 / The marijuana stock market has demonstrated in the first few months of 2019 that the cannabis industry, despite its nascent characteristics, is very much a force to be reckoned with. As a result of lawmakers advocating for, and subsequently passing, legislation in favor of cannabis legalization, companies in the industry have made key investments in products and services, all of which for the purpose of giving all benefits to the consumer. Considering that marijuana is currently flagged as a Schedule I narcotic by the U.S. government, one would assume that this would dampen the progress of the cannabis sector, but, in fact, cannabis companies are showing no signs of slowing down.
Auxly Cannabis Group Inc. (TSX.V - XLY) ("Auxly" or the "Company") today announced that its streaming partner, Lotus Ventures Inc. (“Lotus”), has been granted a “standard cultivation” licence and a “sale for medical purposes” licence by Health Canada pursuant to the Cannabis Act and Cannabis Regulations. The licences give Lotus the ability to begin cultivation at its fully constructed 22,500 square-foot facility in Armstrong, British Columbia (the “Facility”). Hugo Alves, President of Auxly said: “We want to congratulate Dale, Stephen, Scott, Carl, Monica and the rest of the Lotus team on obtaining their Cannabis Act licences! This is an important step for Auxly as we continue to diversify our supply chain, utilizing a network of subsidiaries and partners to provide reliable sources of diverse raw product.
CORAL GABLES, FL / ACCESSWIRE / February 26, 2019 / The marijuana stock market has consistently dominated headlines with news related to positive gains in the market, despite volatile conditions felt by ...
CORAL GABLES, FL / ACCESSWIRE / February 14, 2019 / What's incredible about the marijuana stock market is the sheer amount of excitement surrounding companies in the cannabis industry. As we've seen over the course of the past few years, more countries have brought forth legislation in favor of legalizing marijuana for recreational, as well as medicinal, purposes, and as a result, companies in the space have seen an influx in investor attention. If companies continue like this, the marijuana industry may see impressive gains as a result of favorable public opinions.
Auxly Cannabis Group Inc. (TSX.V - XLY) ("Auxly" or the "Company") is pleased to announce the appointments of Brian Schmitt as Chief Financial Officer, Jason Sonshine as Vice President, Strategy, and Carla Nawrocki as Vice President, Investor Relations of the Company. Brian Schmitt, CFO, is an accomplished finance and accounting executive with approximately 30 years of experience in both private and publicly-traded companies. Most recently, Mr. Schmitt acted as the CFO at EnerCare Inc., where during his tenure with the company he played a large part in growing the company through acquisition and helped carve out their strategy, systems integration and operating plan.
HENDERSON, NV / ACCESSWIRE / February 8, 2019 / January's bull run for the cannabis industry led to a natural correction; it looks like the sector is gaining support for its next push, there are several ...
Auxly Cannabis Group Inc. (TSX.V - XLY) ("Auxly" or the "Company") today announced the termination of the definitive agreement dated March 3, 2018 (the “Agreement”) between the Company and FV Pharma Inc., a wholly-owned subsidiary of FSD Pharma Inc. (“FSD Pharma”) (CSE:HUGE) governing the joint venture between the parties. The joint venture was formed with the intention of developing a portion of FSD Pharma's cannabis cultivation facility located in Cobourg, Ontario (the “JV Facility”) in mutually agreed staged phases (the “JV Facility Development”).
NEW YORK, NY / ACCESSWIRE / February 4, 2019 / Traders News Source, a leading independent equity research and corporate access firm focused on small and mid-cap public companies is issuing a comprehensive report on Auxly Cannabis (CBWTF) a vertically integrated cannabis company. Auxly is creating a world-class platform by forming partnerships with best-in-class cultivators, product innovators, and developers, researchers, and marketers. Auxly is a vertically integrated cannabis company with diverse operations across Canada and Uruguay.
Why Auxly Cannabis Group Stock Grew ~6.75% on January 25Stock performanceOn January 25, on the OTC markets, Auxly Cannabis Group’s stock price closed at $0.72, which is ~6.75% higher than its close of $0.67 on January 24 and reflects ~8% growth
Auxly Cannabis Group Enters Agreement with Curative CannabisDealToday, Auxly Cannabis Group (CBWTF) announced that it entered an agreement with Curative Cannabis for the acquisition of 46% of Curative’s common shares in exchange for the issuance
Auxly Cannabis Group Inc. (XLY.V) (CBWTF) (the "Company") is pleased to announce that the Company has signed a definitive agreement (the “Transaction”) with 2368523 Ontario Limited (d/b/a) Curative Cannabis ("Curative"). The Company will acquire 46% of the common shares of Curative and enter into a long-term cannabis purchase and sale agreement to fund the construction and development costs of Curative’s cannabis cultivation facility in Chatham-Kent, Ontario (the “Facility”). The Facility is designed as a purpose-built indoor facility for the production of ultra-premium cannabis product.
According to data compiled by Brightfield Group, the U.S. CBD market is expected to reach USD 22 Billion by 2022, outpacing the rest of the cannabis market combined. Many are using CBD over other pain relievers such as ibuprofen or opioids. While these over-the-counter pain relievers may help with pain relief and reduce inflammation, they pose risks in the form of many side effects.